Victor Manuel Vargas Blasco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5836931/publications.pdf

Version: 2024-02-01

36303 25787 12,267 135 51 108 citations h-index g-index papers 141 141 141 9034 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. New England Journal of Medicine, 1999, 341, 403-409.	27.0	1,519
2	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
3	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	27.0	817
4	Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. Gastroenterology, 2007, 133, 818-824.	1.3	639
5	Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology, 1990, 12, 716-724.	7.3	587
6	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. Hepatology, 2016, 64, 1249-1264.	7.3	550
7	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	27.8	493
8	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
9	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. New England Journal of Medicine, 1991, 325, 829-835.	27.0	294
10	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
11	The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. Journal of Hepatology, 2001, 35, 598-604.	3.7	233
12	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	3.7	225
13	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
14	Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology, 2003, 38, 51-58.	3.7	212
15	Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology, 2003, 39, 231-238.	3.7	196
16	Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transplantation, 2005, 11, 1242-1251.	2.4	189
17	Minimal Hepatic Encephalopathy Is Associated With Falls. American Journal of Gastroenterology, 2011, 106, 476-482.	0.4	180
18	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178

2

#	Article	IF	Citations
19	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology, 1995, 21, 674-679.	7.3	171
20	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. Journal of Hepatology, 2018, 69, 1250-1259.	3.7	152
21	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	7.3	151
22	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
23	Combined treatment with pegylated interferon (\hat{l} ±-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. Journal of Hepatology, 2005, 43, 53-59.	3.7	148
24	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	3.7	144
25	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	4.8	134
26	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. Journal of Hepatology, 2020, 72, 472-480.	3.7	130
27	Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplantation, 2011, 17, 38-46.	2.4	129
28	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. Journal of Hepatology, 2020, 72, 391-400.	3.7	119
29	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The Lancet Gastroenterology and Hepatology, 2019, 4, 445-453.	8.1	116
30	Molecular Tracing of the Global Hepatitis C Virus Epidemic Predicts Regional Patterns of Hepatocellular Carcinoma Mortality. Gastroenterology, 2006, 130, 703-714.	1.3	106
31	Cognitive dysfunction in cirrhosis is associated with falls: A prospective study. Hepatology, 2012, 55, 1922-1930.	7.3	93
32	Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transplantation, 2006, 12, 95-104.	2.4	89
33	Alfapump \hat{A}^{\otimes} system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. Journal of Hepatology, 2017, 67, 940-949.	3.7	85
34	Resection of hepatocellular carcinoma in patients with cirrhosis. British Journal of Surgery, 2005, 83, 758-761.	0.3	83
35	Efficacy of Albumin Treatment for Patients with CirrhosisÂandÂInfections Unrelated to Spontaneous BacterialÂPeritonitis. Clinical Gastroenterology and Hepatology, 2020, 18, 963-973.e14.	4.4	77
36	Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Journal of Hepatology, 2007, 47, 366-372.	3.7	76

#	Article	IF	Citations
37	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	3.7	76
38	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	8.1	75
39	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	7.3	74
40	The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673.	7.3	67
41	Cytomegalovirus Disease as a Risk Factor for Graft Loss and Death After Orthotopic Liver Transplantation. Clinical Infectious Diseases, 1998, 26, 865-870.	5.8	66
42	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 446-452.	0.4	65
43	Only C-Reactive Protein, but not TNF-α or IL6, Reflects the Improvement in Inflammation after Bariatric Surgery. Obesity Surgery, 2012, 22, 131-139.	2.1	61
44	T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology, 2003, 38, 1026-1033.	7.3	60
45	Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Digestive Diseases and Sciences, 2002, 47, 1356-1361.	2.3	58
46	T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. Journal of Hepatology, 2012, 56, 765-774.	3.7	58
47	Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World Journal of Hepatology, 2012, 4, 382.	2.0	58
48	The Relationships Between IGF-1 and CRP, NO, Leptin, and Adiponectin During Weight Loss in the Morbidly Obese. Obesity Surgery, 2010, 20, 623-632.	2.1	57
49	Lipoprotein Lipase Expression in Livers of Morbidly Obese Patients Could be Responsible for Liver Steatosis. Obesity Surgery, 2009, 19, 608-616.	2.1	54
50	Psychosocial adjustment to orthotopic liver transplantation in 266 recipients. Liver Transplantation, 2004, 10, 228-234.	2.4	53
51	Long interval between HCV infection and development of hepatocellular carcinoma. Liver, 1995, 15, 159-163.	0.1	52
52	Treatment of refractory ascites with an automated lowâ€flow ascites pump in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2017, 46, 981-991.	3.7	46
53	Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Liver International, 1999, 19, 177-182.	3.9	42
54	Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation. Journal of Hepatology, 1996, 24, 452-459.	3.7	41

#	Article	IF	Citations
55	Brain Magnetic Resonance Spectroscopy in Episodic Hepatic Encephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 272-277.	4.3	41
56	A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis. Liver Transplantation, 2018, 24, 1655-1664.	2.4	41
57	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	4.1	39
58	Increased Expression and Activity of Hepatic Lipase in the Liver of Morbidly Obese Adult Patients in Relation to Lipid Content. Obesity Surgery, 2009, 19, 894-904.	2.1	36
59	A Long-Term Study of Changes in the Volume of Brain Ventricles and White Matter Lesions After Successful Liver Transplantation. Transplantation, 2010, 89, 589-594.	1.0	36
60	Ghrelin and Apolipoprotein AIV Levels Show Opposite Trends to Leptin Levels During Weight Loss in Morbidly Obese Patients. Obesity Surgery, 2009, 19, 1414-1423.	2.1	35
61	Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transplantation, 2012, 18, 201-205.	2.4	34
62	Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transplantation, 2002, 8, 892-900.	2.4	33
63	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. American Journal of Transplantation, 2018, 18, 2513-2522.	4.7	32
64	Liver Transplantation in HIV-HCV Coinfected Patients: A Case-Control Study. Transplantation, 2007, 83, 354-358.	1.0	31
65	Biexponential Analysis of Diffusion-Tensor Imaging of the Brain in Patients with Cirrhosis before and after Liver Transplantation. American Journal of Neuroradiology, 2011, 32, 1510-1517.	2.4	30
66	Patients with refractory ascites treated with alfapump \hat{A}^{\odot} system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Quality of Life Research, 2018, 27, 1513-1520.	3.1	30
67	Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplantation Proceedings, 1999, 31, 2464-2465.	0.6	28
68	Lupus anticoagulant and portal hypertension. American Journal of Medicine, 1988, 84, 566-568.	1.5	27
69	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology, 2016, 63, 488-498.	7.3	27
70	Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis. Lupus, 2001, 10, 628-631.	1.6	25
71	Visceral leishmaniasis among liver transplant recipients: An overview. Liver Transplantation, 2008, 14, 1816-1819.	2.4	25
72	Lipoprotein Lipase but Not Hormone-Sensitive Lipase Activities Achieve Normality After Surgically Induced Weight Loss in Morbidly Obese Patients. Obesity Surgery, 2009, 19, 1150-1158.	2.1	23

#	Article	IF	Citations
73	A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Reports, 2021, 3, 100291.	4.9	23
74	Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients. Antiviral Therapy, 2006, 11, 1061-1070.	1.0	23
75	<i>Listeria monocytogenes</i> àêessociated acute hepatitis in a liver transplant recipient. Liver, 1998, 18, 213-215.	0.1	22
76	Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. Hepatology, 2020, 71, 1106-1116.	7.3	22
77	T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology, 2003, 38, 1026-1033.	7.3	22
78	Alterations in the Common Pathway of Coagulation During Weight Loss Induced by Gastric Bypass in Severely Obese Patients. Obesity, 2012, 20, 1048-1056.	3.0	21
79	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	3.9	20
80	Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?. Annals of Hepatology, 2011, 10, 180-187.	1.5	19
81	Predictive model of mortality in patients with spontaneous bacterial peritonitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 629-637.	3.7	19
82	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, 2022, 71, 1856-1866.	12.1	17
83	Soluble CD40 Ligand in Morbidly Obese Patients. JAMA Surgery, 2013, 148, 151.	4.3	16
84	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. Journal of Hepatology, 2021, 74, 200-219.	3.7	16
85	Hyperkalemic Distal Renal Tubular Acidosis Caused by Immunosuppressant Treatment with Tacrolimus in a Liver Transplant Patient: Case Report. Transplantation Proceedings, 2011, 43, 4016-4018.	0.6	15
86	Morbidly "Healthy―Obese Are Not Metabolically Healthy but Less Metabolically Imbalanced Than Those with Type 2 Diabetes or Dyslipidemia. Obesity Surgery, 2015, 25, 1380-1391.	2.1	15
87	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver International, 2020, 40, 1121-1129.	3.9	15
88	OUTCOME OF HEPATITIS C VIRUS-ASSOCIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AFTER LIVER TRANSPLANTATION. Transplantation, 1999, 68, 1131-1134.	1.0	15
89	Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. American Journal of Gastroenterology, 2021, 116, 2250-2257.	0.4	14
90	Pancreatic pseudocyst located in the liver. Revista Espanola De Enfermedades Digestivas, 2006, 98, 616-20.	0.3	14

#	Article	IF	Citations
91	Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transplant International, 1997, 10, 462-465.	1.6	13
92	Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. World Journal of Gastroenterology, 2015, 21, 10475.	3.3	12
93	Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102267.	3.3	12
94	Frailty in outpatients with cirrhosis: A prospective observational study. Liver International, 2021, 41, 357-368.	3.9	12
95	Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. American Journal of Transplantation, 2016, 16, 679-687.	4.7	11
96	High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection, 2017, 23, 775.e1-775.e6.	6.0	11
97	Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. Haemophilia, 2006, 12, 228-236.	2.1	10
98	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology, 1995, 21, 674-679.	7.3	10
99	Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series. Brain and Behavior, 2020, 10, e01596.	2.2	9
100	Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese. BBA Clinical, 2016, 5, 54-65.	4.1	8
101	ANTI-HEPATITIS-A ANTIBODY IN SPAIN. Lancet, The, 1978, 312, 583.	13.7	7
102	Drug-Induced Lupus-Like Reaction and Captopril. Annals of Pharmacotherapy, 1993, 27, 1541-1542.	1.9	7
103	Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. Transplant International, 2003, 16, 270-275.	1.6	7
104	A multicentre, randomized, doubleâ€blind study comparing nocte famotidine or ranitidine for the treatment of active duodenal ulceration. Alimentary Pharmacology and Therapeutics, 1989, 3, 103-110.	3.7	7
105	Clinical laboratory standard capillary protein electrophoresis alerted of a low C3 state and lead to the identification of a Factor I deficiency due to a novel homozygous mutation. Immunology Letters, 2016, 174, 19-22.	2.5	7
106	Trasplante hepático en pacientes con infección por el VIH: una realidad en el año 2004. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 529-538.	0.5	7
107	MATERNOâ€FETAL TRANSMISSION OF HEPATITIS A ANTIBODY. Acta Paediatrica, International Journal of Paediatrics, 1980, 69, 533-533.	1.5	6
108	Etiology and mortality of spontaneous bacterial peritonitis in liver transplant recipients: A cohort study. Liver Transplantation, 2014, 20, 856-863.	2.4	5

#	Article	IF	CITATIONS
109	Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis. Digestive and Liver Disease, 2020, 52, e30.	0.9	5
110	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatology Communications, 2022, 6, 1100-1112.	4.3	5
111	HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS MARKERS IN EUROPE. Lancet, The, 1979, 313, 721-722.	13.7	4
112	A Multicenter, Randomized, Double-Blind Study Comparing a Daily Bedtime Administration of Famotidine and Ranitidine in Short-Term Treatment of Active Duodenal Ulcer. Digestion, 1989, 42, 79-85.	2.3	4
113	Outcome of cirrhotic patients with incidental hepatocellular carcinoma undergoing liver transplantation. Transplantation Proceedings, 2002, 34, 299-300.	0.6	4
114	Routine Bile Culture From Liver Donors as Screening of Donorâ€Transmitted Infections in Liver Transplantation, 2020, 26, 1121-1126.	2.4	4
115	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcoholâ€Associated Hepatitis. Liver Transplantation, 2021, 27, 1382-1391.	2.4	4
116	Does Routine Abdominal Drain Tip Culture Anticipate Post-Operative Infection in Liver Transplantation?. Surgical Infections, 2021, 22, 222-226.	1.4	3
117	Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. Journal of Clinical Medicine, 2022, 11, 2466.	2.4	3
118	246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. Gastroenterology, 2019, 156, S-1186.	1.3	2
119	Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report. World Journal of Hepatology, 2020, 12, 1128-1135.	2.0	2
120	Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. Transplant International, 2003, 16, 270-5.	1.6	2
121	Relevance of positive lymphocytotoxic crossmatch and immunosuppressive regimens in the outcome of liver transplants. Transplantation Proceedings, 1997, 29, 461-462.	0.6	1
122	Sa1579 Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis. Gastroenterology, 2016, 150, S1073-S1074.	1.3	1
123	Evaluation and treatment of the critically ill cirrhotic patient. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 607-626.	0.1	1
124	Mo1454 - Durable Response in the Markers of Cholestasis Through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis. Gastroenterology, 2018, 154, S-1211-S-1212.	1.3	1
125	Patients with Compensated Cirrhosis Are Also at Risk of Falling. Hepatology, 2019, 69, 455-457.	7.3	1
126	Early pleural effusion in histiocytosis X. Archives of Internal Medicine, 1979, 139, 934-936.	3.8	1

#	Article	IF	CITATIONS
127	HAAb TITRES IN HEPATITIS A. Lancet, The, 1979, 313, 610-611.	13.7	О
128	[473] SEROLOGICAL AND MOLECULAR MARKERS OF HEPATITIS B VIRUS IN SPANISH BLOOD DONORS: EVIDENCE OF OCCULT HEPATITIS B. Journal of Hepatology, 2007, 46, S179-S180.	3.7	0
129	Doubtful Role of IL28B Polymorphism in Occult Hepatitis B Infection. Intervirology, 2015, 58, 160-165.	2.8	0
130	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 535-538.	1.6	0
131	Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections. Results from the ICA "Global Study― Digestive and Liver Disease, 2018, 50, 23-24.	0.9	0
132	Mo1468 – Long Term Assessment of the Effects of Obeticholic Acid in Patients with Primary Biliary Cholangitis on Immune and Inflammatory Markers. Gastroenterology, 2019, 156, S-1317.	1.3	0
133	PTU-009 \hat{a} Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers. , 2019, , .		0
134	326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY. Gastroenterology, 2020, 158, S-1268.	1.3	0
135	Value of pilot studies in alcoholâ€associated hepatitis. Liver International, 2022, 42, 1697-1697.	3.9	0